Lifeward (LFWD) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Fri, May 15, 2026 astatine 12:00 PM CDT 15 min read

Image source: The Motley Fool.

DATE

Friday, May 15, 2026 astatine 8:30 a.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — William Grant

• Chief Financial Officer — Almog Adar

Full Conference Call Transcript

William Grant: Thank you, Almog, and convey you for everybody for joining america today. The archetypal 4th of 2026 marked an important strategical milestone for Lifeward arsenic we successfully completed the acquisition of Oratech. We judge this transaction importantly strengthens Lifeward's presumption arsenic a diversified biomedical innovation institution portion reinforcing our absorption connected neurorehabilitation and our way toward profitability. We judge this was a highly strategical and capital-efficient transaction for Lifeward shareholders. Through the equity-based acquisition of Oratech, we gained entree to the macromolecule oral transportation platform, a perchance transformative exertion crossed galore therapeutic indications, including ORMD-0801 oral insulin, which is expected to commence a Phase II study.

Importantly, the objective programme absorption responsibilities stay with Oramed, utilizing funds antecedently transferred to Oratech arsenic portion of the strategical transaction. That means Lifeward and our shareholders by owning the macromolecule orally delivered level outright efficaciously person a meaningful enactment connected the imaginable occurrence of the promising exertion with minimal near-term operational burden, nary worldly summation successful operating expenses and constricted absorption bandwidth requirements beyond my ain involvement, supporting strategical oversight and improvement guidance. As galore of you know, my inheritance includes extended acquisition successful diabetes and metabolic disease, and I judge this level has meaningful semipermanent potential. At the aforesaid time, Lifeward's halfway absorption remains firmly centered connected scaling our neurorehabilitation MedTech business.

The 2nd cardinal takeaway from the 4th is Lifeward is present substantially amended positioned connected its way to profitability. With the $10 cardinal from our convertible enactment financing, we person importantly strengthened our equilibrium expanse and improved our operating flexibility. This allows america to stabilize and physique upon the cardinal and foundational enactment we person done implicit the past respective quarters, portion maintaining our disciplined absorption connected operational efficiency, marketplace entree and innovation crossed our neuro rehabilitation platform. We expect continued operational stabilization implicit the adjacent respective quarters arsenic our baseline resets pursuing our manufacturing modulation initiatives completed implicit the past twelvemonth and the consummation of the important transaction this quarter.